{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:52:15Z","timestamp":1790985135614,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["CZ.02.01.01\/00\/23_020\/0008560"],"award-info":[{"award-number":["CZ.02.01.01\/00\/23_020\/0008560"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["NU22-04-00143"],"award-info":[{"award-number":["NU22-04-00143"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neuroinflammation is increasingly recognized as a core pathophysiological mechanism in schizophrenia and can be indirectly assessed through peripheral inflammatory markers. Therefore, this pilot study investigated the impact of antipsychotic treatment on inflammation in patients with first-episode psychosis (FEP) who were antipsychotic-naive at study entry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty-three drug-na\u00efve FEP patients provided blood samples upon admission (V0) and follow-up (V1), from which peripheral inflammatory markers\u2014i.e., neutrophil\/lymphocyte ratio (NLR), monocyte\/lymphocyte ratio (MLR), platelet\/lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)\u2014were calculated. Antipsychotic doses during continuous hospitalization between V0 and V1 (34 days, IQR: 21\u201349 days) were converted into cumulative chlorpromazine equivalents (cCPZ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In multiple regression models adjusting for sex, age, BMI, DUP, and clozapine use, cumulative antipsychotic exposure significantly predicted reductions in \u0394NLR (p = 0.048), \u0394MLR (p = 0.041), \u0394PLR (p = 0.028), and \u0394SII (p = 0.028). All associations remained significant following false discovery rate adjustment (pFDR = 0.048 for all outcomes).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest a consistent dose-dependent anti-inflammatory effect during early antipsychotic treatment in FEP. Given the exploratory nature of this study, larger studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1769162","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:34:35Z","timestamp":1771310075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Antipsychotics lower peripheral markers of inflammation in drug-na\u00efve early psychosis: a pilot study"],"prefix":"10.3389","volume":"17","author":[{"given":"Nicole","family":"\u0160af\u00e1\u0159ov\u00e1","sequence":"first","affiliation":[{"name":"Early Episodes of SMI Research Center, National Institute of Mental Health","place":["Klecany, Czechia"]},{"name":"Department of Clinical Pharmacy, 3rd Faculty of Medicine, Charles University","place":["Prague, Czechia"]},{"name":"Psychiatric Hospital Bohnice","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1n","family":"Koleni\u010d","sequence":"additional","affiliation":[{"name":"Early Episodes of SMI Research Center, National Institute of Mental Health","place":["Klecany, Czechia"]},{"name":"Department of Clinical Pharmacy, 3rd Faculty of Medicine, Charles University","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Ta\u0161kov\u00e1","sequence":"additional","affiliation":[{"name":"Psychiatric Hospital Bohnice","place":["Prague, Czechia"]},{"name":"Faculty of Pharmacy, Charles University","place":["Hradec Kr\u00e1lov\u00e9, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e1clav","family":"\u010capek","sequence":"additional","affiliation":[{"name":"Early Episodes of SMI Research Center, National Institute of Mental Health","place":["Klecany, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"F\u00fcrstov\u00e1","sequence":"additional","affiliation":[{"name":"Early Episodes of SMI Research Center, National Institute of Mental Health","place":["Klecany, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"\u0160paniel","sequence":"additional","affiliation":[{"name":"Early Episodes of SMI Research Center, National Institute of Mental Health","place":["Klecany, Czechia"]},{"name":"Department of Clinical Pharmacy, 3rd Faculty of Medicine, Charles University","place":["Prague, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.MS21078COM5","article-title":"The epidemiology and global burden of schizophrenia","volume-title":"J Clin Psychiatry","author":"Velligan","year":"2023"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr Bull"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32647-8","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s11920-007-0041-7","article-title":"Dopamine hypothesis of schizophrenia: making sense of it all","volume":"9","author":"Toda","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v11.i7.355","article-title":"History of the dopamine hypothesis of antipsychotic action","volume":"11","author":"Seeman","year":"2021","journal-title":"World J Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(99)00105-0","article-title":"Limitations of dopamine-D2 antagonists and the search for novel antipsychotic strategies","volume":"21","author":"Marder","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1192\/bjp.183.5.427","article-title":"Cost-effectiveness of current and optimal treatment for schizophrenia","volume":"183","author":"Andrews","year":"200","journal-title":"Br J Psychiatry: J Ment Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.schres.2015.04.040","article-title":"Motivational deficits in early schizophrenia: prevalent, persistent, and key determinants of functional outcome","volume":"166","author":"Fervaha","year":"2015","journal-title":"Schizophr Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbu099","article-title":"Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project","volume":"41","author":"Perkins","year":"2015","journal-title":"Schizophr Bull"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/acps.13416","article-title":"Inflammation in first-episode psychosis: the contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis","volume":"146","author":"Dunleavy","year":"2022","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.581061","article-title":"Neutrophil-to-lymphocyte ratio is independently associated with severe psychopathology in schizophrenia and is changed by antipsychotic administration: A large-scale cross-sectional retrospective study","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Psychiatry\/Frontiers Res Foundation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41537-024-00437-5","article-title":"The neutrophil-to-lymphocyte ratio is associated with clinical symptoms in first-episode medication-na\u00efve patients with schizophrenia","volume":"10","author":"Wang","year":"2024","journal-title":"Schizophr (Heidelberg Germany)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1114595","DOI":"10.1016\/j.pnpbp.2025.111459","article-title":"Beyond dopamine: exploring anti-inflammatory mechanisms of antipsychotics","volume":"141","author":"\u0160af\u00e1\u0159ov\u00e1","year":"2025","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.30773\/pi.2018.12.19.1","article-title":"Peripheral biomarkers for first-episode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia","volume":"16","author":"Trov\u00e3o","year":"2019","journal-title":"Psychiatry Invest"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105200","DOI":"10.1016\/j.psyneuen.2021.105200","article-title":"Immune-inflammatory markers and psychosis risk: A systematic review and meta-analysis","volume":"127","author":"Misiak","year":"2021","journal-title":"Psychoneuroendocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.728990","article-title":"Is elevated neutrophil count and neutrophil-to-lymphocyte ratio a cause or consequence of schizophrenia?-A scoping review","volume":"12","author":"Sandberg","year":"2021","journal-title":"Front Psychiatry\/Frontiers Res Foundation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2018.12.017","article-title":"Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis","volume":"206","author":"Karageorgiou","year":"2019","journal-title":"Schizophr Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2017.03.003","article-title":"Acute variations of cytokine levels after antipsychotic treatment in drug-na\u00efve subjects with a first-episode psychosis: A meta-analysis","volume":"77","author":"Capuzzi","year":"2017","journal-title":"Neurosci Biobehav Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"155441","DOI":"10.1016\/j.cyto.2021.155441","article-title":"Serum interleukin-6 in schizophrenia: A system review and meta-analysis","volume":"141","author":"Zhou","year":"2021","journal-title":"Cytokine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.278","article-title":"Inflammation and the neural diathesis-stress hypothesis of schizophrenia: A reconceptualization","volume":"7","author":"Howes","year":"2017","journal-title":"Trans Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s00213-015-3975-1","article-title":"Is there a role for immune-to-brain communication in schizophrenia","volume":"233","author":"Khandaker","year":"2016","journal-title":"Psychopharmacology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.4049\/jimmunol.173.6.3916","article-title":"Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs","volume":"173","author":"Olson","year":"2004","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"a016303","DOI":"10.1101\/cshperspect.a016303","article-title":"The chemokine system in innate immunity","volume":"7","author":"Sokol","year":"2015","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2024.03.010","article-title":"Innate immune activation in neurodegenerative diseases","volume":"57","author":"Castro-Gomez","year":"2024","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1080\/15622975.2019.1583371","article-title":"Neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio in non-affective psychosis: A meta-analysis and systematic review","volume":"21","author":"Mazza","year":"2020","journal-title":"World J Biol Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01416","article-title":"Crosstalk between astrocytes and microglia: an overview","volume":"11","author":"Matejuk","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-022-02976-3","article-title":"Linking inflammation, aberrant glutamate-dopamine interaction, and post-synaptic changes: translational relevance for schizophrenia and antipsychotic treatment: A systematic review","volume":"59","author":"de Bartolomeis","year":"2022","journal-title":"Mol Neurobiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.3390\/jcm10112488","article-title":"A meta-analysis of the influence of antipsychotics on cytokines levels in first episode psychosis","volume":"10","author":"Marcinowicz","year":"2021","journal-title":"J Clin Med Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.neuropharm.2016.12.025","article-title":"Paliperidone reverts toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia","volume":"116","author":"MacDowell","year":"2017","journal-title":"Neuropharmacology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2015.05.021","article-title":"The effect of the antipsychotic drug quetiapine and its metabolite norquetiapine on acute inflammation, memory and anhedonia","volume":"135","author":"Jaehne","year":"2015","journal-title":"Pharmacol Biochem Behav"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1121585","DOI":"10.1016\/j.intimp.2024.112158","article-title":"Anti-inflammatory and protective effects of aripiprazole on TNBS-induced colitis and associated depression in rats: role of kynurenine pathway","volume":"133","author":"Mohammadgholi-Beiki","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1117975","DOI":"10.1016\/j.mad.2023.111797","article-title":"Sex differences in markers of oxidation and inflammation. Implications for ageing","volume":"211","author":"Mart\u00ednez de Toda","year":"2023","journal-title":"Mech Ageing Dev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"a041197","DOI":"10.1101\/cshperspect.a041197","article-title":"Aging and inflammation","volume":"14","author":"Singh","year":"2024","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/02537176251317648","article-title":"Can non-specific blood inflammatory biomarkers predict recovery in acute transient psychotic disorder? A prospective observational study","author":"Prakash","year":"2025","journal-title":"Indian J psychol Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41537-023-00398-1","article-title":"Inflammatory markers of symptomatic remission at 6 months in patients with first-episode schizophrenia","volume":"9","author":"Kim","year":"2023","journal-title":"Schizophr (Heidelberg Germany)"},{"key":"B39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41380-022-01718-0","article-title":"The neurobiology of duration of untreated psychosis: A comprehensive review","volume":"28","author":"Zoghbi","year":"2023","journal-title":"Mol Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.numecd.2023.09.002","article-title":"Differences in the levels of inflammatory markers between metabolically healthy obese and other obesity phenotypes in adults: A systematic review and meta-analysis","volume":"34","author":"Su","year":"2024","journal-title":"Nutrition Metabolism Cardiovasc Diseases: NMCD"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The american psychiatric association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"112727","DOI":"10.1016\/j.psychres.2019.112727","article-title":"Pattern of expression of toll like receptor (TLR)-3 and -4 genes in drug-na\u00efve and antipsychotic treated patients diagnosed with schizophrenia","volume":"285","author":"Balaji","year":"2020","journal-title":"Psychiatry Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbad171","article-title":"Toll-like receptor mRNA levels in schizophrenia: association with complement factors and cingulate gyrus cortical thinning","volume":"50","author":"Weickert","year":"2024","journal-title":"Schizophr Bull"},{"key":"B44","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12974-019-1652-8","article-title":"Dopamine receptor D3 signaling in astrocytes promotes neuroinflammation","volume":"16","author":"Montoya","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14601","article-title":"Targeting dopamine receptor D3 signaling in inflammation","volume":"8","author":"Pacheco","year":"2017","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00394","article-title":"The cross-talk between the dopaminergic and the immune system involved in schizophrenia","volume":"11","author":"Vidal","year":"2020","journal-title":"Front Pharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663102","article-title":"Immunomodulatory effects of dopamine in inflammatory diseases","volume":"12","author":"Feng","year":"2021","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2023.01.042","article-title":"Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: A systematic review and meta-analysis","volume":"160","author":"Patlola","year":"2023","journal-title":"J Psychiatr Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"13365","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales","year":"2019","journal-title":"Cells (Basel Switzerland)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1769162\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:34:36Z","timestamp":1771310076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1769162\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":50,"alternative-id":["10.3389\/fpsyt.2026.1769162"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1769162","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1769162"}}